The National Health Surveillance Agency (Anvisa) in Brazil has recently alerted the public to the rare risks of liver inflammation and damage associated with dietary supplements and medications containing turmeric, also known as saffron. This alert comes as a response to international evaluations that have reported suspected cases of liver toxicity among individuals using turmeric products, particularly capsules or concentrated extracts. The agency emphasizes that the risk is primarily related to formulations designed to enhance the absorption of curcumin, the active compound in turmeric, which can result in significantly higher doses than those typically ingested through food consumption.

Anvisa's warning is part of a broader concern that has prompted similar alerts from regulatory authorities in several countries, including Italy, Australia, Canada, and France. These nations have also issued health warnings regarding turmeric supplements, underscoring a growing recognition of the potential hazards associated with high-dose intake. As the public becomes increasingly interested in natural supplements and the perceived health benefits of turmeric, agencies like Anvisa are tasked with ensuring that the products available on the market meet safety standards and are used responsibly.

Consumers are encouraged to exercise caution and to consult healthcare professionals before taking turmeric supplements, particularly those in concentrated forms. The agency's alert serves as a reminder of the importance of regulatory oversight in the dietary supplement industry, aiming to prevent adverse health events and promote informed consumption practices. As more research emerges, it will be crucial for both consumers and health authorities to stay updated on the safety profiles of such popular natural products.